Blue Water Vaccines Reports Third Quarter 2022 Financial Results and Recent Business Highlights; Announces 5 Million Share Repurchase Program
November 10, 2022 08:47 ET
|
Blue Water Vaccines Inc.
Closed private placement in August 2022, with net proceeds of approximately $8.7 millionAnnounced plans to evaluate efficacy of BWV-201 for protection against non-invasive pneumococcal pneumonia in...
The Worldwide Legionella Testing Industry is Projected to Reach $439 Million by 2027
September 14, 2022 05:58 ET
|
Research and Markets
Dublin, Sept. 14, 2022 (GLOBE NEWSWIRE) -- The "Legionella Testing Market by Test Type (Culture, Urinary Antigen Test, DFA, PCR), Application (Water & IVD Testing (Urine, Blood)), End User...
At 6% CAGR, Pneumonia Testing Market Size to Hit USD 912.5 Million by 2029
August 16, 2022 08:22 ET
|
Fortune Business Insights
Pune, India, Aug. 16, 2022 (GLOBE NEWSWIRE) -- The global pneumonia testing market size hit USD 557.1 million in 2021. The market valuation is slated to rise from USD 606.6 million in 2022 to USD...
Global Legionella Testing Market (2022 to 2027) - Industry Trends, Share, Size, Growth, Opportunity and Forecasts
June 17, 2022 08:28 ET
|
Research and Markets
Dublin, June 17, 2022 (GLOBE NEWSWIRE) -- The "Legionella Testing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to...
Insights on the Infection Surveillance Solutions Global Market to 2027 - by Component, Deployment Type, End-user and Region
June 07, 2022 08:13 ET
|
Research and Markets
Dublin, June 07, 2022 (GLOBE NEWSWIRE) -- The "Infection Surveillance Solutions Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to...
BioAegis Therapeutics Completes $22 Million Institutional Sale of Equity in a Non-Brokered Transaction
March 22, 2022 05:00 ET
|
BioAegis Therapeutics
NORTH BRUNSWICK, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, Inc., a clinical-stage, private company developing therapies for inflammatory, infectious, and degenerative diseases...
BioAegis Therapeutics Announces Appointment of Two New Corporate Board Members
February 17, 2022 17:42 ET
|
BioAegis Therapeutics
NORTH BRUNSWICK, N.J., Feb. 17, 2022 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, Inc., a clinical-stage, private company developing therapies for inflammatory, infectious, and degenerative diseases...
BioAegis’ Novel Host-directed Human Protein for Inflammatory Diseases Geared for Growth in 2022
January 24, 2022 15:52 ET
|
BioAegis Therapeutics
NORTH BRUNSWICK, N.J., Jan. 24, 2022 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical-stage, private company developing therapies for infectious, inflammatory and degenerative diseases...
Global Interventional Pulmonology Market Report 2021-2025 with Regional Analysis of Bronchoscopy Examination Procedures
January 20, 2022 05:03 ET
|
Research and Markets
Dublin, Jan. 20, 2022 (GLOBE NEWSWIRE) -- The "Global Interventional Pulmonology Market: Size, Trends & Forecast with Impact Analysis of COVID-19 (2021-2025)" report has been added to...
Insights on the Hospital-Acquired Infection Control Global Market to 2030 - Upsurge in Likelihood of Epidemic or Pandemic Outbreaks is Driving Growth
December 21, 2021 06:38 ET
|
Research and Markets
Dublin, Dec. 21, 2021 (GLOBE NEWSWIRE) -- The "Hospital-Acquired Infection Control Market by Product & Service and End User: Global Opportunity Analysis and Industry Forecast, 2022-2030" report...